Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases.
The ketogenic diet as a treatment paradigm for diverse neurological disorders.
Role of the Blood-Brain Barrier in Multiple Sclerosis.
Acorda Therapeutics announces positive AMPYRA® (dalfampridine) Phase 2 data in people with post-stroke deficits
[Controlled research on multiple sclerosis treated with electroacupuncture and acupoint injection].
Reduced serum orexin-A levels in autoimmune encephalitis and neuromyelitis optica patients.
The investigation of acute optic neuritis: a review and proposed protocol.
Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.
Visual Functional and Histopathological Correlation in Experimental Autoimmune Optic Neuritis.
Effectiveness of Natalizumab in Patients with Highly Active Relapsing Remitting Multiple Sclerosis.
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.
iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF.
A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica).
Reproductive issues in women with multiple sclerosis: ethical considerations.
Prevention and treatment of MS: studying the effects of vitamin D.
A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis.
Clinical overview of the seizure risk of dalfampridine.
B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis.
Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients. Effects of long-term treatment on immunologic parameters.
Ceramide Synthase 6 Plays a Critical Role in the Development of Experimental Autoimmune Encephalomyelitis.
Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001-2010.
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.
The International Symposium on the Multiple Sclerosis Brain

Pages